Graves Orbitopathy Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Date : Mar 2018

Formats :
Report Code : PMR83649629

Category : Pharmaceutical and Healthcare
No Of Pages :
Global Graves Orbitopathy Market


Graves’ ophthalmopathy is also called as thyroidassociated orbitopathy TAO and thyroid eye disease TED, Graves’ orbitopathy GO is autoimmune inflammatory disorder of the tissues of periorbit and orbit that is characterized by the retraction of upper eyelid, lagging, swelling and redness of lid, bulging of eyes and conjunctivitis. Most commonly occurs in the individuals having Graves’ disease, and less commonly in the individuals having Hashimoto’s thyroiditis, or in the people with euthyroid. It is a part of systemic process of variable expression in skin, thyroid and eyes that is caused by the autoantibodies which binds to the tissues of these organs. Autoantibodies targets the fibroblasts in the eye muscles and fibroblasts can be differentiated into the fat cells adipocytes. Muscles and fat cells expands and get inflammation.



Increase in incidence and prevalence of thyroid disorders, availability of appreciative reimbursement policies for the treatment, and growing awareness regarding the complications related to thyroid disorders are some of the factors driving Graves’ disease market. Side effects associated with drugs are one of the restraints for the graves orbitopathy market.



The global graves orbitopathy market is segmented on the basis of drug class, distribution channel and geographical regions.



Based on the drug class, the graves orbitopathy market is segmented as:

Iodine and Iodides
Ionic Inhibitors
Radioactive Iodine
Beta Blockers
Thioamides
Corticosteroids


Based on the distribution channel, the graves orbitopathy market is segmented as:

Hospital Pharmacies
Retail Pharmacies
Others


As per Wickham study in England, in 2017, Graves’ disease is accounted for 0.5 cases per 1000 persons, with high incidence rate in people with age of 40 to 60. Graves’ disease is the high prevalent autoimmune disorder in U.S After Hashimoto thyroiditis. In 2017, as per research study of PREGO presentation of Graves orbitopathy, incidence of Graves’ orbitopathy in Europe was 1030/10,000 human annually. However, severity and the incidence of the Graves’ disease in Europe was observed to decline to 2.10/10,000/year. Iodine131 is used in radioactive iodine ablation RIA used to remove whole or a part of thyroid gland, which results in preventing the excessive production of thyroid hormone. Subtotal thyroidectomy used for the removal of thyroid gland is the most invasive treatment option.





On the basis of geographical regions, the graves’ orbitopathy market is segmented as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected as major market for the disorders related to thyroid gland followed by Europe. AsiaPacific is expected to be as a rapidly growing market due to rise in thyroid gland disorders, rise in health care investments, growing awareness regarding hyperthyroidism, and different alternative treatments availability.



Some of the players in the graves orbitopathy disease market are GlaxoSmithKline plc U.K., Allergan, plc.Ireland Abbott Laboratories U.S. RLC LABS U.S., AbbVie, Inc. U.S., Mylan N.V. U.S., Pfizer, Inc. U.S., and Merck & Co.,Inc. U.S.



In September 2014, Avalon Ventures and GlaxoSmithKline plc launced two new companies with US $10 Mn each in series a financing and R&D support companies include Silarus Therapeutics developing treatments for anaemia and iron overload disorders and Thyritope Biosciences developing treatments for grave’s orbitopathy
1. Executive Summary
2. Global Graves Orbitopathy Market Introduction
2.1. Global Graves Orbitopathy Market – Taxonomy
2.2. Global Graves Orbitopathy Market –Definitions
2.2.1. Drug Class
2.2.2. Distribution Channel
3. Global Graves Orbitopathy Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Graves Orbitopathy Market Dynamics – Factors Impact Analysis
3.6. Global Graves Orbitopathy Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.6.3. Japan
4. Global Graves Orbitopathy Market Analysis, 2013 2017 and Forecast, 2018 – 2024
4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
4.2. YearoverYear YoY Growth Analysis %
4.3. Market Oppurtunity Analysis
5. Global Graves Orbitopathy Market, By Drug Class, 2013 2017 and Forecast, 2018 2024
5.1. Iodine and Iodides
5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.1.3. Market Opportunity Analysis
5.2. Ionic Inhibitors
5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.2.3. Market Opportunity Analysis
5.3. Radioactive Iodine
5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.3.3. Market Opportunity Analysis
5.4. Beta Blockers
5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.4.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.4.3. Market Opportunity Analysis
5.5. Thioamides
5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.5.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.5.3. Market Opportunity Analysis
5.6. Corticosteroids
5.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.6.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.6.3. Market Opportunity Analysis
6. Global Graves Orbitopathy Market Forecast, By Distribution Channel, 2013 2017 and Forecast, 2018 2024
6.1. Hospital Pharmacies
6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.3.3. Market Opportunity Analysis
7. Global Graves Orbitopathy Market Forecast, By Region, 2013 2017 and Forecast, 2018 2024
7.1. North America
7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.2.3. Market Opportunity Analysis
7.3. AsiaPacific
7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.4.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.5.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.5.3. Market Opportunity Analysis
7.6. Global Graves Orbitopathy Market Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Region, 2018 – 2024
8. North America Graves Orbitopathy Market Analysis, 2013 2017 and Forecast, 2018 2024
8.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
8.1.1. Iodine and Iodides
8.1.2. Ionic Inhibitors
8.1.3. Radioactive Iodine
8.1.4. Beta Blockers
8.1.5. Thioamides
8.1.6. Corticosteroids
8.2. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Others
8.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
8.3.1. U.S.
8.3.2. Canada
8.4. North America Graves Orbitopathy Market Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2018 – 2024
8.5. North America Graves Orbitopathy Market Dynamics – Trends
9. Europe Graves Orbitopathy Market Analysis, 2013 2017 and Forecast, 2018 2024
9.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
9.1.1. Iodine and Iodides
9.1.2. Ionic Inhibitors
9.1.3. Radioactive Iodine
9.1.4. Beta Blockers
9.1.5. Thioamides
9.1.6. Corticosteroids
9.2. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.2.3. Others
9.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Poland
9.3.8. Rest of Europe
9.4. Europe Graves Orbitopathy Market Opportunity Analysis Index, By Drug Class, By Distribution Channel and Country, 2018 – 2024
9.5. Europe Graves Orbitopathy Market Dynamics – Trends
10. AsiaPacific Graves Orbitopathy Market Analysis, 2013 2017 and Forecast, 2018 2024
10.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
10.1.1. Iodine and Iodides
10.1.2. Ionic Inhibitors
10.1.3. Radioactive Iodine
10.1.4. Beta Blockers
10.1.5. Thioamides
10.1.6. Corticosteroids
10.2. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
10.2.1. Hospital Pharmacies
10.2.2. Retail Pharmacies
10.2.3. Others
10.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn,
YoY Growth %, and Market Share %
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of AsiaPacific
10.4. AsiaPacific Graves Orbitopathy Market Opportunity Analysis Index, By Drug Class, By Distribution Channel and Country, 2018 – 2024
10.5. AsiaPacific Graves Orbitopathy Market Dynamics – Trends
11. Latin America Graves Orbitopathy Market Analysis, 2013 2017 and Forecast, 2018 2024
11.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
11.1.1. Iodine and Iodides
11.1.2. Ionic Inhibitors
11.1.3. Radioactive Iodine
11.1.4. Beta Blockers
11.1.5. Thioamides
11.1.6. Corticosteroids
11.2. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
11.2.1. Hospital Pharmacies
11.2.2. Retail Pharmacies
11.2.3. Others
11.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Venezuela
11.3.5. Rest of Latin America
11.4. Latin America Graves Orbitopathy Market Opportunity Analysis Index, By Drug Class, By Distribution Channel and Country, 2018 – 2024
11.5. Latin America Graves Orbitopathy Market Dynamics – Trends
12. Middle East and Africa Graves Orbitopathy Market Analysis, 2013 2017 and Forecast, 2018 2024
12.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
12.1.1. Iodine and Iodides
12.1.2. Ionic Inhibitors
12.1.3. Radioactive Iodine
12.1.4. Beta Blockers
12.1.5. Thioamides
12.1.6. Corticosteroids
12.2. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
12.2.1. Hospital Pharmacies
12.2.2. Retail Pharmacies
12.2.3. Others
12.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
12.3.1. Gulf Cooperation Council GCC Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Graves Orbitopathy Market Opportunity Analysis Index, By Drug Class, By Distribution Channel and Country, 2018 – 2024
12.5. MEA Graves Orbitopathy Market Dynamics – Trends
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis
13.2.1. Abbott Laboratories U.S.
13.2.2. Alimera Sciences U.S.
13.2.3. Allergan plc Ireland.
13.2.4. Ampio Pharmaceuticals. U.S.
13.2.5. Bayer AG Germany
13.2.6. F. HoffmannLa Roche Switzerland
13.2.7. Novartis AG Switzerland
13.2.8. Pfizer Inc. U.S.
13.2.9. Regeneron Pharmaceuticals Inc. U.S.
13.2.10. Valeant Canada
14. Research Methodology
15. Key Assumptions and Acronyms
  Purchase Options for Report

Need More information

Call us :
USA : +1 7162260907
UK : +44 7441952057
....
sales@planetmarketreports.com

Why to choose PMR

PMR Market Research

Our syndicated research reports cover 50+ industry sectors offering you product and country wise breakup of the market along with niche data and insights that will help you make informed business decision. Our research is focused on the key segments of an industry that possess opportunities of growth.

  • Industrial ...
  • Business ....
  • Consumer ....
  • Peer ....

About Report

Planet Market Reports added Latest and detailed market study report that focuses on “Graves Orbitopathy Market" Which offers essential information based on fresh ideas into Graves Orbitopathy Market industry along with unique market analysis which covers current top Manufactures in Graves Orbitopathy Market, growth, Consumption Demand, challenges, Historical data, subjects wise Survey of each chapters, Regional Insights, and Advancing industry trends, which will help our clients to aim Graves Orbitopathy Market. In addition, the report helps the customers to get a brief idea about Future demand and specifications of products which ensures the driving long-term income and productivity of global market.


Similar Reports

No Records Found...